查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1499575

HIV 臨床試驗市場：按階段、試驗設計、介入類型、市場參與企業、贊助商 - 2024-2030 年全球預測

HIV Clinical Trials Market by Phase (Phase I, Phase II, Phase III), Study Design (Expanded Access Studies, Interventional Studies, Observational Studies), Type of Intervention, Participant, Sponsor - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年HIV臨床試驗市場規模為11.5億美元，預計2024年將達12.3億美元，2030年將達到18.8億美元，複合年成長率為7.20%。

HIV 臨床試驗涉及嚴格的測試過程和預防或治癒人類免疫力缺乏病毒 (HIV) 感染的新治療方法、藥物和療法的研究工作。鑑於愛滋病毒的多樣性及其對不同人群的影響，臨床試驗對於提高醫學知識和治療能力至關重要。以愛滋病毒為重點的臨床試驗對於推進醫學知識和製定更有效的策略來預防、檢測和治療愛滋病毒至關重要。全球愛滋病毒感染者人數不斷增加，迫切需要有效的治療方法，並擴大了愛滋病毒臨床試驗的數量。關於愛滋病毒預防和治療的意識提升宣傳活動正在促使研究人員擴大愛滋病毒臨床試驗。與愛滋病毒治療相關的倫理問題阻礙了市場的成長。活性化的愛滋病毒研發活動和政府資助的增加為愛滋病毒臨床試驗市場創造了成長機會。

主要市場統計
基準年[2023] 11.5億美元
預測年份 [2024] 12.3億美元
預測年份 [2030] 18.8億美元
複合年成長率（%） 7.20%

區域洞察

在雄厚的資金和先進的醫療保健系統的推動下，美洲的愛滋病毒臨床試驗數量持續增加。在大量政府和私人投資的支持下，美洲在愛滋病毒研究和發展方面處於世界領先地位。包括總統愛滋病緊急救援計畫 (PEPFAR) 在內的舉措表明了對國內和世界各地消除愛滋病毒工作的堅定承諾。隨著人們對愛滋病毒預防的認知不斷提高，南美洲的愛滋病毒臨床試驗正迅速擴大。亞太地區高度發達，研究中心迅速增加，政府對新治療方法和疫苗研究投入大量資金。儘管日本的愛滋病毒發病率較低，但它在涉及愛滋病毒的科學研究上投入了大量資金。印度人口眾多，愛滋病毒感染率高，使其成為臨床試驗以及政府和國際共同投資的重要國家，特別是在學名藥和負擔得起的醫療保健解決方案的生產方面。歐盟（EU）國家在歐盟和國家資助機構的支持下積極參與愛滋病毒臨床試驗。在中東和非洲，由於愛滋病毒感染率高，特別是在撒哈拉以南非洲地區，針對愛滋病毒的臨床試驗數量逐漸增加。研究也著重於了解影響這些地區人口的獨特遺傳和環境因素，這對於根據當地需求制定干涉措施至關重要。

FPNV定位矩陣

FPNV 定位矩陣對於評估供應商在 HIV 臨床試驗市場中的定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可對 HIV 臨床試驗市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外，該分析還提供了對該行業競爭性質的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在愛滋病毒臨床試驗市場中的地位進行全面評估，使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地感染愛滋病的人數不斷增加
      • 製藥公司和非營利組織增加了對愛滋病毒臨床試驗的投資活動
    • 抑制因素
      • 與愛滋病毒臨床試驗相關的高成本以及相關的研發成本
    • 機會
      • 政府增加愛滋病毒治療和藥物的核准
      • HIV臨床試驗技術和解決方案的進展
    • 任務
      • HIV 臨床試驗藥物處方的複雜性
  • 市場區隔分析
    • 階段：增加 III 期臨床試驗的數量，以提供新的治療方法
    • 贊助：增加製藥和生物製藥公司的贊助，以提高藥品的商業性可用性
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章 HIV 臨床試驗市場：依階段、研究設計、介入類型、市場階段

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第7章 HIV 臨床試驗市場：階段、試驗設計、介入類型、市場研究設計

  • 擴大訪問研究
  • 干預研究
  • 觀察性研究

第8章 HIV 臨床試驗市場：依階段、試驗設計、介入類型、市場介入類型

  • 藥物治療
  • 疫苗

第9章 HIV 臨床試驗市場：依階段、研究設計、介入類型和市場參與企業

  • 成人
  • 小兒科
  • 懷孕的女人

第 10 章 HIV 臨床試驗市場：階段、試驗設計、介入類型、市場贊助商

  • 非營利機構
  • 製藥和生物製藥公司

第11章美洲愛滋病毒臨床試驗市場：階段、試驗設計、介入類型、市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區愛滋病毒臨床試驗市場：階段、研究設計、介入類型、市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第 13 章：歐洲、中東和非洲 HIV 臨床試驗市場：階段、研究設計、介入類型和市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 愛滋病臨床試驗小組的臨床試驗旨在提高愛滋病毒治療的有效性和安全性
    • 研究表明，在不同人群中，注射劑卡博特韋在預防愛滋病毒方面優於口服 PrEP。
    • ReiThera、Ragon Institute 和 IAVI 開始創新 T 細胞 HIV 疫苗 HIVconsvX 的 I 期試驗
  • 戰略分析和建議

第15章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-7C50F273957B

[182 Pages Report] The HIV Clinical Trials Market size was estimated at USD 1.15 billion in 2023 and expected to reach USD 1.23 billion in 2024, at a CAGR 7.20% to reach USD 1.88 billion by 2030.

The HIV clinical trials involve rigorous testing processes and research activities where new treatments, drugs, and therapies are intended to prevent or cure human immunodeficiency virus (HIV) infection. Given the diversity of HIV and its impact on various demographic segments, the trials are vitally important in progressing medical knowledge and treatment capabilities. Clinical trials focused on HIV are crucial for advancing medical knowledge and developing more effective strategies for the prevention, detection, and treatment of HIV. The growing number of HIV cases globally fuels urgency and the need for effective treatments, subsequently expanding the number of HIV clinical trials. Enhanced awareness campaigns about HIV prevention and treatment encourage researchers to expand the clinical trials for HIV. Ethical concerns associated with the treatment of HIV hamper the market growth. Increasing research & development activities for HIV with rising government funding creates opportunities for the growth of the HIV clinical trials market.

KEY MARKET STATISTICS
Base Year [2023] USD 1.15 billion
Estimated Year [2024] USD 1.23 billion
Forecast Year [2030] USD 1.88 billion
CAGR (%) 7.20%

Regional Insights

In the Americas, the number of HIV clinical trials is continuously increasing due to robust funding and advanced healthcare systems. The Americas leads in global HIV research and development, supported by significant government and private investment. Initiatives, including, the President's Emergency Plan for AIDS Relief (PEPFAR), demonstrate a strong commitment to not only domestic but also global HIV control efforts. The HIV clinical trials in South America are rapidly expanding with rising awareness associated with the prevention of HIV. Asia-Pacific region is highly developing with rapidly increasing its research footprint and significant government investment in new therapies and vaccine research. Japan, while having a lower incidence of HIV, invests heavily in scientific research, including HIV. India's large population and high HIV prevalence make it a significant country for clinical trials, with both government and international collaborative investments, particularly in generic drug manufacturing and affordable healthcare solutions. European Union countries actively participate in HIV clinical trials, backed by EU and national funding bodies. In the Middle East and Africa, the number of clinical trials focusing on HIV is gradually increasing, driven by a high prevalence of the disease, particularly in sub-Saharan Africa. The research also emphasizes understanding the unique genetic and environmental factors affecting the population in these regions, which is critical for tailoring interventions to local needs.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the HIV Clinical Trials Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing prevalence of AIDS disease worldwide
      • Growing investment activities by pharmaceutical and non-profit organizations for HIV clinical trials
    • Market Restraints
      • High costs associated with HIV clinical trials and associated research & development costs
    • Market Opportunities
      • Rising governmental approvals for HIV drugs and medications
      • Advancements in HIV clinical trial technologies and solutions
    • Market Challenges
      • Complexities in drug formulation of HIV clinical trials
  • Market Segmentation Analysis
    • Phase: Increasing the number of phase III clinical trials to make the new treatments available
    • Sponsor: Increasing sponsorship from pharmaceutical & biopharmaceutical companies to enhance commercial availability of medications
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the HIV Clinical Trials Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the HIV Clinical Trials Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Clinical Trial by AIDS Clinical Trials Group Seeks to Enhance HIV Treatment Efficacy and Safety

The AIDS Clinical Trials Group (ACTG), a renowned entity in HIV research, has recently launched a new clinical trial aimed at improving treatment strategies for HIV. This trial, referred to as the most significant of its kind in recent history, focuses on testing the effectiveness and safety of an innovative drug regimen. This regimen redefines standard care by enhancing its efficacy, reducing side effects, and simplifying treatment protocols. Through meticulous research and participant monitoring, the ACTG hopes to provide substantial evidence to influence future treatment guidelines and optimize outcomes for individuals living with HIV. [Published On: 2024-04-19]

Study Shows Injectable Cabotegravir Surpasses Oral PrEP in HIV Prevention Across Diverse Groups

ViiV Healthcare announced successful results from clinical trials of cabotegravir, a long-acting injectable formulation. This innovative treatment, administered bi-monthly, has shown high efficacy in reducing the risk of HIV infection across diverse population groups. In these trials, cabotegravir outperformed daily oral pre-exposure prophylaxis (PrEP), demonstrating fewer HIV infections among participants who received the injection compared to those who took oral PrEP. These findings mark a promising advancement in HIV prevention strategies, offering an effective and more convenient alternative for individuals at risk of HIV, potentially improving adherence and overall public health outcomes. [Published On: 2024-03-04]

ReiThera, Ragon Institute, and IAVI Launch Phase I Trials for Innovative T-Cell HIV Vaccine, HIVconsvX

ReiThera Srl, the Ragon Institute, and IAVI have embarked on a collaborative initiative to progress a promising T-cell HIV vaccine candidate, HIVconsvX, into Phase I clinical evaluation. This collaborative effort marks a significant step in HIV vaccine research, focusing on a vaccine designed to trigger a broad and potent immune response. By targeting highly conserved regions across various HIV strains, HIVconsvX aims to provide robust protection against this globally prevalent virus. The advancement to Phase I trials showcases the potential of this innovative approach and underscores the collaborative model among leading research institutions and biotech firms in pioneering solutions for some of the most challenging health issues. [Published On: 2024-01-22]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the HIV Clinical Trials Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the HIV Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., American Gene Technologies Inc, AstraZeneca PLC, Bayer AG, BioNTech SE, Boehringer Ingelheim International GmbH, Cipla Ltd., CSL Limited, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Emcure Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna, Inc., Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the HIV Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Phase
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Study Design
    • Expanded Access Studies
    • Interventional Studies
    • Observational Studies
  • Type of Intervention
    • Drug Therapy
    • Vaccines
  • Participant
    • Adults
    • Pediatric
    • Pregnant Women
  • Sponsor
    • Non Profit Organizations
    • Pharmaceutical & Biopharmaceutical Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of AIDS disease worldwide
      • 5.1.1.2. Growing investment activities by pharmaceutical and non-profit organizations for HIV clinical trials
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with HIV clinical trials and associated research & development costs
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising governmental approvals for HIV drugs and medications
      • 5.1.3.2. Advancements in HIV clinical trial technologies and solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities in drug formulation of HIV clinical trials
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Phase: Increasing the number of phase III clinical trials to make the new treatments available
    • 5.2.2. Sponsor: Increasing sponsorship from pharmaceutical & biopharmaceutical companies to enhance commercial availability of medications
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. HIV Clinical Trials Market, by Phase

  • 6.1. Introduction
  • 6.2. Phase I
  • 6.3. Phase II
  • 6.4. Phase III
  • 6.5. Phase IV

7. HIV Clinical Trials Market, by Study Design

  • 7.1. Introduction
  • 7.2. Expanded Access Studies
  • 7.3. Interventional Studies
  • 7.4. Observational Studies

8. HIV Clinical Trials Market, by Type of Intervention

  • 8.1. Introduction
  • 8.2. Drug Therapy
  • 8.3. Vaccines

9. HIV Clinical Trials Market, by Participant

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Pediatric
  • 9.4. Pregnant Women

10. HIV Clinical Trials Market, by Sponsor

  • 10.1. Introduction
  • 10.2. Non Profit Organizations
  • 10.3. Pharmaceutical & Biopharmaceutical Companies

11. Americas HIV Clinical Trials Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific HIV Clinical Trials Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa HIV Clinical Trials Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Clinical Trial by AIDS Clinical Trials Group Seeks to Enhance HIV Treatment Efficacy and Safety
    • 14.3.2. Study Shows Injectable Cabotegravir Surpasses Oral PrEP in HIV Prevention Across Diverse Groups
    • 14.3.3. ReiThera, Ragon Institute, and IAVI Launch Phase I Trials for Innovative T-Cell HIV Vaccine, HIVconsvX
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. HIV CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 2. HIV CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. HIV CLINICAL TRIALS MARKET DYNAMICS
  • FIGURE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. HIV CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. HIV CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HIV CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS STUDIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS STUDIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON PROFIT ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON PROFIT ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 77. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 78. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 87. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 88. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 89. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 90. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 97. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 98. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 122. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 124. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 131. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 132. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 133. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 134. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 141. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 142. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 143. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 144. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 151. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 152. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 153. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 154. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 161. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 162. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 163. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 164. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 171. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 172. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 173. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 174. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 182. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 184. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 191. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 192. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 193. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 194. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 202. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 204. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 211. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 212. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 213. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 214. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 221. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 222. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 223. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 224. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 231. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 232. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 233. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 234. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 253. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 254. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 255. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 256. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 263. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 264. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 265. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 266. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 273. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 274. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 275. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 276. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 277. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 278. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 283. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 284. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 285. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 286. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 287. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 288. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 293. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 294. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 295. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 296. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 297. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 298. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 299. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 300. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 301. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 302. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 303. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 304. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 305. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 306. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 307. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 308. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 309. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 310. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 311. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 312. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 313. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 314. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 315. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 316. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 317. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 318. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 319. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 320. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 321. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 322. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 324. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 326. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 328. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 330. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 332. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 333. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 334. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 335. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 336. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 337. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 338. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 339. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 340. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 341. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 342. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 343. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 344. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 345. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 346. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 347. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 348. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 349. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 350. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPA